Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Imlunestrant on CYP2C8, CYP2C19, CYP2D6, P-gp, and BCRP Activity and the Effect of P-gp Inhibition on Imlunestrant Pharmacokinetics in Healthy Women of Non-childbearing Potential

NCT05444556 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05444556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05444556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Imlunestrant on CYP2C8, CYP2C19, CYP2D6, P-gp, and BCRP Activity and the Effect of P-gp Inhibition on Imlunestrant Pharmacokinetics in Healthy Women of Non-childbearing Potential
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
July 7, 2022
Completion date
November 2, 2022
Enrollment
113 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy